Abstract:The cellular prion protein, PrP C , has been postulated to function as a receptor for α-synuclein, potentially facilitating cell-to-cell spreading and/or toxicity of α-synuclein aggregates in neurodegenerative disorders such as Parkinson's disease. Previously, we generated the "Salt (S)" and "No Salt (NS)" strains of α-synuclein aggregates that cause distinct pathological phenotypes in M83 transgenic mice overexpressing A53T-mutant human α-synuclein. To test the hypothesis that PrP C facilitates the propagation of α-synuclein aggregates, we produced M83 mice that either express or do not express PrP C . Following intracerebral inoculation with the S or NS strain, the absence of PrP C in M83 mice did not prevent disease development and had minimal influence on α-synuclein strain-specified attributes such as the extent of cerebral α-synuclein deposition, selective targeting of specific brain regions and cell types, the morphology of induced α-synuclein deposits, and the structural fingerprints of protease-resistant α-synuclein aggregates. Likewise, there were no appreciable differences in disease manifestation between PrP C -expressing and PrP C -lacking M83 mice following intraperitoneal inoculation of the S strain. Interestingly, intraperitoneal inoculation with the NS strain resulted in two distinct disease phenotypes, indicative of α-synuclein strain evolution, but this was also independent of PrP C expression. Overall, these results suggest that PrP C plays at most a minor role in the propagation, neuroinvasion, and evolution of α-synuclein strains in mice that express A53T-mutant human α-synuclein. Thus, other putative receptors or cell-to-cell propagation mechanisms may have a larger effect on the spread of α-synuclein aggregates during disease. During Parkinson's disease and related neurodegenerative disorders, the protein α-synuclein clumps together in the brain to form aggregates. α-Synuclein aggregates can spread between cells, and this process is believed to underlie disease progression. Thus, blocking the spread of α-synuclein aggregates may be a good therapeutic strategy for preventing the progression of Parkinson's disease. The details of how α-synuclein aggregates spread from cell to cell in the brain remain unclear, but it has been proposed that the cellular prion protein (PrP C ) may facilitate spreading by acting as a receptor for α-synuclein aggregates. However, this notion remains controversial. In this study, we compared the spread of α-synuclein aggregates within and to the brain in mice that either possessed or lacked PrP C . We found that the spreading of α-synuclein aggregates was largely independent of the presence of PrP C . This suggests that PrP C may not be an effective therapeutic target for attenuating the spread of α-synuclein aggregates in Parkinson's disease.

Low-density lipoprotein receptor-related protein 1 mediates α-synuclein transmission from the striatum to the substantia nigra in animal models of Parkinson's disease

Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease

Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease

Intercellular transmission of alpha-synuclein

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

Initiation and propagation of α-synuclein aggregation in the nervous system

α-Synuclein strain propagation is independent of cellular prion protein expression in a transgenic synucleinopathy mouse model

Alpha-synuclein Promotes Clathrin-Mediated Endocytosis of NMDA Receptors in Dopaminergic Cells

From inflammasome to Parkinson’s disease: Does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson’s disease?

Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration

Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease

Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal

Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methylesterase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α-Synuclein

Parkinson's Disease Derived Exosomes Aggravate Neuropathology in SNCA*A53T Mice

Selective Trafficking of Non-Cell-Autonomous Proteins Mediated by NtNCAPP1

The Spreading and Effects of Human Recombinant {alpha}-Synuclein Preformed Fibrils in the Cerebrospinal Fluid of Mice

Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson's disease

Microglial exosomes facilitate α-synuclein transmission in Parkinson's disease

Aldh1a1 and additional markers of dopamine cell heterogeneity in substantia nigra and ventral tegmental area identified as preserved in two transgenic α-synuclein mouse models of neurodegenerative disease

α-Synuclein Aggregates in the Nigro-Striatal Dopaminergic Pathway Impair Fine Movement: Partial Reversal by the Adenosine A2A Receptor Antagonist